Point72 Asia Singapore Pte. Ltd. Trims Stock Position in Repligen Co. (NASDAQ:RGEN)

Point72 Asia Singapore Pte. Ltd. lowered its stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 98.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 206 shares of the biotechnology company's stock after selling 13,770 shares during the period. Point72 Asia Singapore Pte. Ltd.'s holdings in Repligen were worth $30,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the stock. Point72 Asset Management L.P. raised its stake in shares of Repligen by 183.1% during the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock valued at $132,227,000 after buying an additional 594,189 shares during the last quarter. Polar Asset Management Partners Inc. raised its stake in shares of Repligen by 76.9% during the 4th quarter. Polar Asset Management Partners Inc. now owns 6,900 shares of the biotechnology company's stock valued at $993,000 after buying an additional 3,000 shares during the last quarter. ProShare Advisors LLC raised its stake in shares of Repligen by 7.4% during the 4th quarter. ProShare Advisors LLC now owns 2,438 shares of the biotechnology company's stock valued at $351,000 after buying an additional 167 shares during the last quarter. Quantinno Capital Management LP raised its stake in shares of Repligen by 80.0% during the 4th quarter. Quantinno Capital Management LP now owns 3,523 shares of the biotechnology company's stock valued at $507,000 after buying an additional 1,566 shares during the last quarter. Finally, LRT Capital Management LLC raised its stake in shares of Repligen by 6.9% during the 4th quarter. LRT Capital Management LLC now owns 4,274 shares of the biotechnology company's stock valued at $615,000 after buying an additional 276 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the company. Evercore ISI initiated coverage on Repligen in a research note on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price objective for the company. HC Wainwright restated a "buy" rating and issued a $180.00 price target on shares of Repligen in a research note on Monday, May 5th. JPMorgan Chase & Co. cut their price target on Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research note on Tuesday, April 29th. Canaccord Genuity Group cut their price target on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research note on Wednesday, April 16th. Finally, Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target for the company in a research note on Tuesday, April 29th. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Repligen presently has a consensus rating of "Moderate Buy" and an average target price of $173.25.

Insiders Place Their Bets

In related news, Director Margaret Pax bought 250 shares of the stock in a transaction dated Monday, March 17th. The shares were acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the acquisition, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.20% of the stock is owned by company insiders.

Repligen Price Performance

NASDAQ:RGEN opened at $126.19 on Tuesday. Repligen Co. has a 12 month low of $102.97 and a 12 month high of $182.52. The stock has a 50 day moving average of $132.36 and a two-hundred day moving average of $145.11. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. The firm has a market cap of $7.09 billion, a P/E ratio of -247.43, a price-to-earnings-growth ratio of 4.54 and a beta of 1.21.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.35 by $0.04. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. During the same period in the previous year, the business earned $0.28 EPS. Repligen's quarterly revenue was up 10.4% on a year-over-year basis. On average, analysts expect that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.